Enhancing the Management of Metastatic Tumors by Robust Co-delivery of 5-fluorouracil/microRNA-10b inhibitor Using EGFR-targeted Nanovehicles.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced healthcare materials"
DOI: 10.1002/adhm.202202989
Abstract: Invasion and metastasis of colorectal cancer (CRC) are the leading causes of death of patients with CRC. 5-fluorouracil (5-FU) has been widely used in clinic practice as the basic chemotherapy drug for CRC. However, it… read more here.
Keywords: metastasis; egfr targeted; 10b inhibitor; microrna 10b ... See more keywords
Protease-activated receptor 2 stabilizes Bcl-xL and regulates EGFR-targeted therapy response in colorectal cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer letters"
DOI: 10.1016/j.canlet.2021.05.040
Abstract: The Bcl-2 homolog Bcl-xL is emerging as a key factor in tumorigenesis due to its prominent pro-survival and cell death-independent functions. However, the regulation of Bcl-xL by microenvironment and its implication in cancer therapy of… read more here.
Keywords: par2; egfr targeted; protease activated; activated receptor ... See more keywords
STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Sign Up to like & getrecommendations! Published in 2017 at "Molecular and Cellular Endocrinology"
DOI: 10.1016/j.mce.2017.01.010
Abstract: Several EGFR inhibitors are currently undergoing clinical assessment or are approved for the clinical management of patients with varying tumour types. However, treatment often results in a lack of response in many patients. The majority… read more here.
Keywords: egfr targeted; tumour resistance; signaling mediates; resistance ... See more keywords
NIR-II Navigation with an EGFR-Targeted Probe Improves Imaging Resolution and Sensitivity of Detecting Micrometastases in Esophageal Squamous Cell Carcinoma Xenograft Models.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00115
Abstract: The survival rate of esophageal squamous carcinoma (ESCC) after surgical resection is estimated to be only 30.3% due to the difficulty in identifying microinfiltration and subtle metastases. In this study, we explored the value of… read more here.
Keywords: targeted probe; egfr targeted; escc; esophageal squamous ... See more keywords
111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells††Electronic supplementary information (ESI) available: Supplementary figures and tables. See DOI: 10.1039/c7nr09606b
Sign Up to like & getrecommendations! Published in 2018 at "Nanoscale"
DOI: 10.1039/c7nr09606b
Abstract: EGFR-targeted PLGA nanoparticles co-deliver the Auger electron emitter 111In and a ruthenium(ii) radiosensitizer for combined therapeutic effects. read more here.
Keywords: ruthenium; polymeric nanoparticles; labelled polymeric; egfr targeted ... See more keywords
P14.111 Successful treatment of extensive metastatic disease with successive use of two different EGF receptor antagonists: case report and review of the literature
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz126.346
Abstract: EGFR-targeted agents can be useful in the treatment of systemic metastatic cancer including that which has spread to the brain. We present the case of a patient with two different EGFR mutations that responded to… read more here.
Keywords: egfr targeted; successful treatment; treatment; disease ... See more keywords
Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms
Sign Up to like & getrecommendations! Published in 2020 at "Science Advances"
DOI: 10.1126/sciadv.aav7416
Abstract: Paclitaxel failure promotes collateral resistance to EGFR-targeted therapy by adaptive rewiring of the cellular stress response. Secondary drug resistance stems from dynamic clonal evolution during the development of a prior primary resistance. This collateral type… read more here.
Keywords: egfr targeted; targeted therapy; collateral resistance; acquired resistance ... See more keywords
FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0232
Abstract: Purpose: Recurrent and/or metastatic unresectable cutaneous squamous cell carcinomas (cSCCs) are treated with chemotherapy or radiotherapy, but have poor clinical responses. A limited response (up to 45% of cases) to EGFR-targeted therapies was observed in… read more here.
Keywords: resistance egfr; egfr targeted; resistance; egfr ... See more keywords
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.15211
Abstract: EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification… read more here.
Keywords: egfr targeted; cadherin expression; targeted therapy; treatment ... See more keywords
Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2019.12.97
Abstract: Background About 20-30% EGFR-mutant non-small lung cancer show intrinsic resistance to EGFR targeted therapies. Compared to T790M positive in acquired resistance patients, little is known about EGFR-TKI intrinsic resistance for T790M negative patients. Methods Thirty-one… read more here.
Keywords: egfr targeted; free dna; cell free; intrinsic resistance ... See more keywords
Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.614363
Abstract: Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are among the most effective immunotherapeutic agents across pre-clinical cancer models. However, clinical development of full-length 4-1BB agonistic mAbs, has been hampered by dose-limiting liver toxicity.… read more here.
Keywords: human egfr; egfr targeted; liver; 1bb agonistic ... See more keywords